Interplay Between Epigenetics and Reactive Oxygen Species in Tumor Radioresistance: Mechanisms and Therapeutic Strategies for Radiotherapy.
- 1Department of Medical and Radiation Oncology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Abstract
Radiotherapy efficacy is constrained by tumor radioresistance, which arises in part from the interplay between reactive oxygen species (ROS) and epigenetic regulation. This review systematically synthesizes the bidirectional "epigenetics-ROS interactive network" that governs tumor radiosensitivity. We propose that this network operates through three core principles: stress adaptation (acute ROS triggers transient epigenetic adjustments for redox recovery), malignant reinforcement (chronic ROS drives stable epigenetic reprogramming toward therapy resistance), and contextual determinacy (cellular outcomes depend on integrated ROS-epigenetic patterns rather than individual signals). Mechanistically, we delineate four regulatory layers including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling, through which the epigenetic machinery controls ROS homeostasis, and conversely, how radiation-induced ROS reshape the epigenetic landscape via oxidative modification of epigenetic enzymes and signaling pathways. These bidirectional interactions form feedback circuits that ultimately dictate whether cells undergo repair, senescence, apoptosis, or ferroptosis. Based on this mechanism, we propose a context-dependent decision framework that matches four distinct combination strategies (ROS amplification, epigenetic priming, hypoxia relief, and multi-pathway cell death induction) with four tumor subtypes defined by their oxidative and epigenetic profiles. We also identify five translational roadblocks including toxicity, delivery inefficiency, manufacturing scalability, regulatory uncertainty, and preclinical-clinical discordance. Resolving these barriers is essential for unlocking the therapeutic potential of this regulatory axis. Strategically targeting the epigenetics-ROS network offers a transformative paradigm for overcoming radioresistance and personalizing cancer radiotherapy.
Related
- The Role of Neutrophil Extracellular Traps (NETosis) in Systemic Lupus Erythematosus: Molecular Mechanisms, Pathogenic Roles, Diagnostic Biomarkers, and Emerging Therapeutic Strategies
- β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies.
- Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies.
- Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies
- Molecular Mechanisms of the Gut-Liver-Placenta Axis in Intrahepatic Cholestasis of Pregnancy: Microbiota-Associated Pathogenesis and Next-Generation Therapeutic Strategies.
BibTeX
@article{yang2026interplay,
title = {{Interplay Between Epigenetics and Reactive Oxygen Species in Tumor Radioresistance: Mechanisms and Therapeutic Strategies for Radiotherapy.}},
author = {Zhengmao Yang and Jiaxin Wang and Guofang Wang and Jiamin Zhu and Shengnan Zhang and Wenjian Guo},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72388},
url = {https://europepmc.org/article/MED/42885567},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Interplay Between Epigenetics and Reactive Oxygen Species in Tumor Radioresistance: Mechanisms and Therapeutic Strategies for Radiotherapy.
AU - Zhengmao Yang
AU - Jiaxin Wang
AU - Guofang Wang
AU - Jiamin Zhu
AU - Shengnan Zhang
AU - Wenjian Guo
PY - 2026
DA - 2026/10/01
JO - Cancer medicine
DO - 10.1002/cam4.72388
UR - https://europepmc.org/article/MED/42885567
AB - Radiotherapy efficacy is constrained by tumor radioresistance, which arises in part from the interplay between reactive oxygen species (ROS) and epigenetic regulation. This review systematically synthesizes the bidirectional "epigenetics-ROS interactive network" that governs tumor radiosensitivity. We propose that this network operates through three core principles: stress adaptation (acute ROS triggers transient epigenetic adjustments for redox recovery), malignant reinforcement (chronic ROS drives stable epigenetic reprogramming toward therapy resistance), and contextual determinacy (cellular outcomes depend on integrated ROS-epigenetic patterns rather than individual signals). Mechanistically, we delineate four regulatory layers including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling, through which the epigenetic machinery controls ROS homeostasis, and conversely, how radiation-induced ROS reshape the epigenetic landscape via oxidative modification of epigenetic enzymes and signaling pathways. These bidirectional interactions form feedback circuits that ultimately dictate whether cells undergo repair, senescence, apoptosis, or ferroptosis. Based on this mechanism, we propose a context-dependent decision framework that matches four distinct combination strategies (ROS amplification, epigenetic priming, hypoxia relief, and multi-pathway cell death induction) with four tumor subtypes defined by their oxidative and epigenetic profiles. We also identify five translational roadblocks including toxicity, delivery inefficiency, manufacturing scalability, regulatory uncertainty, and preclinical-clinical discordance. Resolving these barriers is essential for unlocking the therapeutic potential of this regulatory axis. Strategically targeting the epigenetics-ROS network offers a transformative paradigm for overcoming radioresistance and personalizing cancer radiotherapy.
SN - 2045-7634
ER -